Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobodyAlejandro Rojas‐Fernández, Yorka Cheuquemilla, Yago Margolles et al.|Scientific Reports|2021Cited by 52
A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variantsNaphak Modhiran, Daniel Watterson, Simon Lauer et al.|iScience|2023Cited by 17
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity NanobodyAlejandro Rojas‐Fernández, Ronald Jara, Daniel Watterson et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 16
Development and evaluation of an 18F-labeled nanobody to target SARS-CoV-2's spike proteinSara Lopes van den Broek, Matthias M. Herth, Rocío García‐Vázquez et al.|Frontiers in Nuclear Medicine|2022Cited by 1
An alpaca-derived nanobody recognizes a unique conserved epitope and retains potent activity against the SARS-CoV-2 omicron variantNaphak Modhiran, Daniel Watterson, Simon Lauer et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 0